eCite Digital Repository

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

Citation

Wong, KK and Alty, JE and Goy, AG and Raghav, S and Reutens, DC and Kempster, PA, A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease, Movement Disorders, 26, (8) pp. 1552-1555. ISSN 0885-3185 (2011) [Refereed Article]

DOI: doi:10.1002/mds.23687

Abstract

Background: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.

Methods: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.

Results: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).

Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties.

Item Details

Item Type:Refereed Article
Keywords:parkinson's, dyskinesia, randomised control trial
Research Division:Biomedical and Clinical Sciences
Research Group:Neurosciences
Research Field:Central nervous system
Objective Division:Health
Objective Group:Clinical health
Objective Field:Efficacy of medications
UTAS Author:Alty, JE (Dr Jane Alty)
ID Code:145421
Year Published:2011
Web of Science® Times Cited:23
Deposited By:Wicking Dementia Research and Education Centre
Deposited On:2021-07-21
Last Modified:2021-09-03
Downloads:0

Repository Staff Only: item control page